Halozyme (HALO) Raises 2024 Financial Guidance, Stock Up 13% [Yahoo! Finance]
Halozyme Therapeutics, Inc. (HALO)
Last halozyme therapeutics, inc. earnings: 2/24 04:02 pm
Check Earnings Report
US:NASDAQ Investor Relations:
halozyme.com/investors/default.aspx
Company Research
Source: Yahoo! Finance
This was based on the company's announcement made earlier this week that it has been granted a new patent in the EU that covers the ENHANZE rHuPH20 product, which is produced using the company's proprietary ENHANZE manufacturing methods. Per Halozyme, the new patent is included in all of HALO's existing and future ENHANZE licenses, meaning that all of its licensees will benefit from this patent. The patent is set to be validated in 37 EU countries, where it will be legally recognized and enforceable, until the expiry date of Mar 6, 2029. This enhances the company's competitive edge and provides security for its product and associated technologies. The increased 2024 financial guidance and five-year financial outlook now reflect the original royalty rate for J&J 's JNJ Darzalex (daratumumab) subcutaneous (SC) in the EU which is facilitated by the new EU patent grant for ENHANZE. The patent is expected to ensure Halozyme's financial stability and sustained revenues from this partne
Show less
Read more
Impact Snapshot
Event Time:
HALO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
HALO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
HALO alerts
High impacting Halozyme Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
HALO
News
- argenx Highlights Breadth of Autoimmune Pipeline with New Multifocal Motor Neuropathy Data at 2024 Peripheral Nerve Society Annual Meeting [Yahoo! Finance]Yahoo! Finance
- Halozyme Therapeutics, Inc. (NASDAQ: HALO) had its price target raised by analysts at Benchmark Co. from $50.00 to $60.00. They now have a "buy" rating on the stock.MarketBeat
- Halozyme Announces Roche's OCREVUS® SC with ENHANZE® Receives European Commission Approval for Relapsing and Primary Progressive Multiple Sclerosis [Yahoo! Finance]Yahoo! Finance
- Halozyme Announces Roche's OCREVUS® SC with ENHANZE® Receives European Commission Approval for Relapsing and Primary Progressive Multiple SclerosisPR Newswire
- Halozyme Therapeutics (NASDAQ:HALO) shareholder returns have been stellar, earning 193% in 5 years [Yahoo! Finance]Yahoo! Finance
HALO
Earnings
- 5/7/24 - Beat
HALO
Sec Filings
- 6/20/24 - Form 4
- 6/18/24 - Form 144
- 6/14/24 - Form 4
- HALO's page on the SEC website